Phase 1 Study of Anti-PD-1 Antibody MK-3475 and Peginterferon Alfa-2b for Advanced Melanoma

Trial Profile

Phase 1 Study of Anti-PD-1 Antibody MK-3475 and Peginterferon Alfa-2b for Advanced Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2023.
    • 17 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Results from phase Ib portion of this study (n=24) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top